

Europe Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

<https://marketpublishers.com/r/E415B96D3FCFEN.html>

Date: September 2025

Pages: 140

Price: US\$ 3,450.00 (Single User License)

ID: E415B96D3FCFEN

Abstracts

The European human microbiome market is projected to grow significantly, reaching approximately USD 999.66 million by 2031, up from USD 204.79 million in 2023, reflecting a compound annual growth rate (CAGR) of 21.9% from 2023 to 2031.

Executive Summary and Market Analysis

The market is divided into key regions: France, Germany, the UK, and the Rest of Europe. Europe plays a crucial role in the global human microbiome market and is anticipated to experience strong growth during the period from 2023 to 2031. This growth is driven by an increase in research studies focused on the human microbiome and a rise in chronic diseases and disorders. Additionally, the expansion of various research initiatives related to human microbiomes is expected to be a primary factor propelling market growth in Europe.

Market Segmentation Analysis

The Europe human microbiome market can be analyzed through several key segments: type, application, and disease type.

- By Type: The market is categorized into products and software/services. In 2023, the product segment dominated the market, which is further divided into probiotics and prebiotics.

- By Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.

- By Disease Type: The market is classified into categories such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with GIT

issues leading the market in 2023.

Market Outlook

The growth and dynamics of the human microbiome industry are significantly influenced by investments from major market players. These companies are heavily investing in research and development to create innovative probiotics, diagnostics, and microbiome-based treatments. Such investments foster innovation, leading to the discovery of new strains, mechanisms of action, and therapeutic applications. Clinical trials, which require substantial funding, are essential for validating the safety and efficacy of microbiome-related products.

For instance, Kanvas Biosciences, a leader in microbiome mapping technology, secured USD 12 million in a Pre-Series A funding round in June 2023. This funding will support the advancement of their proprietary platform technology aimed at revolutionizing drug development for microbiome-related diseases. Furthermore, collaborations among companies enhance resource sharing, expertise, and technological advancements, accelerating product development. A notable partnership was formed in July 2023 between Nestlé, the largest food and beverage company globally, and APC Microbiome Ireland, a leading research center, focusing on various aspects of the human microbiome to develop new health-enhancing products. Currently, around 120 companies are investing in microbiome analysis, with numerous startups entering the sector. Key investors include Flagship Pioneering, Seventure Partners, and BioGaia, indicating that increased investment from these players is likely to drive market growth.

Country Insights

The European human microbiome market includes countries such as the UK, Germany, France, Italy, Spain, and others. Germany emerged as the largest market in 2023, recognized as a significant hub for biotechnological research in Europe and globally. This is attributed to the presence of major biotechnology firms, advanced research facilities, and substantial funding for research and development. The ongoing R&D activities and favorable government regulations for microbiome therapeutics development in Germany present lucrative opportunities. For example, in 2022, Vagisan ProBioFlora, produced by Dr. Wolff Group, was reclassified and received medicinal product status, positively impacting the broader microbiome-driven pharmaceutical industry.

In March 2023, mbiomics GmbH announced a successful first closing of its Series A financing round, raising EUR 13 million (approximately USD 15 million), led by MIG Capital with participation from High-Tech Gr?nderfonds, Bayern Kapital, and private investors. Mbiomics utilizes its proprietary high-resolution profiling platform to design effective microbial consortia for precision therapies and improve patient selection and monitoring in clinical trials.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies such as expansion, product innovation, and mergers and acquisitions to enhance their product offerings and increase market share.

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe human microbiome market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the Europe human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe human microbiome market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Companies

MaaT Pharma

Ferring Holdings SA

AOBiome Therapeutics Inc

Finch Therapeutics Group Inc

Seres Therapeutics Inc

Merck & Co Inc

Rebiotix, Inc.

Yakult Honsha Co., Ltd.

IFF Nutrition & Biosciences

Synthetic Biologics, Inc.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:

4. EUROPE HUMAN MICROBIOME MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis

5. EUROPE HUMAN MICROBIOME MARKET – KEY MARKET DYNAMICS

- 5.1 Market Drivers
 - 5.1.1 Significant Investments by Key Market Players
 - 5.1.2 Government Initiatives
- 5.2 Market Restraints
 - 5.2.1 Challenges During Production of Microbiome
- 5.3 Market Opportunities
 - 5.3.1 Robust Investment in Research and Development
- 5.4 Future Trends
 - 5.4.1 Emergence of Precision Medicine
- 5.5 Impact of Drivers and Restraints:

6. HUMAN MICROBIOME MARKET – EUROPE ANALYSIS

6.1 Europe Human Microbiome Market Revenue (US\$ Million), 2021–2031

6.2 Europe Human Microbiome Market Forecast Analysis

7. EUROPE HUMAN MICROBIOME MARKET ANALYSIS – BY TYPE

7.1 Product

7.1.1 Overview

7.1.2 Product: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

7.2 Software and Services

7.2.1 Overview

7.2.2 Software and Services: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

8. EUROPE HUMAN MICROBIOME MARKET ANALYSIS – BY APPLICATION

8.1 Therapeutics

8.1.1 Overview

8.1.2 Therapeutics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

8.2 Diagnostics

8.2.1 Overview

8.2.2 Diagnostics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

8.3 Research

8.3.1 Overview

8.3.2 Research: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

9. EUROPE HUMAN MICROBIOME MARKET ANALYSIS – BY DISEASE TYPE

9.1 Obesity

9.1.1 Overview

9.1.2 Obesity: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

9.2 Diabetes

9.2.1 Overview

9.2.2 Diabetes: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

9.3 Autoimmune Disorder

9.3.1 Overview

9.3.2 Autoimmune Disorder: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

9.4 Cancer

9.4.1 Overview

9.4.2 Cancer: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

9.5 GIT

9.5.1 Overview

9.5.2 GIT: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

9.6 Others

9.6.1 Overview

9.6.2 Others: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10. EUROPE HUMAN MICROBIOME MARKET – COUNTRY ANALYSIS

10.1 Europe

10.1.1 Europe Human Microbiome Market – Revenue and Forecast Analysis – by Country

10.1.1.1 Europe Human Microbiome Market – Revenue and Forecast Analysis – by Country

10.1.1.2 United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.1.1.2.1 United Kingdom: Europe Human Microbiome Market Share – by Type

10.1.1.2.2 United Kingdom: Europe Human Microbiome Market Share – by Product

10.1.1.2.3 United Kingdom: Europe Human Microbiome Market Share – by

Application

10.1.1.2.4 United Kingdom: Europe Human Microbiome Market Share – by Disease Type

10.1.1.3 Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

10.1.1.3.1 Germany: Europe Human Microbiome Market Share – by Type

10.1.1.3.2 Germany: Europe Human Microbiome Market Share – by Product

10.1.1.3.3 Germany: Europe Human Microbiome Market Share – by Application

- 10.1.1.3.4 Germany: Europe Human Microbiome Market Share – by Disease Type
- 10.1.1.4 France: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.1.1.4.1 France: Europe Human Microbiome Market Share – by Type
 - 10.1.1.4.2 France: Europe Human Microbiome Market Share – by Product
 - 10.1.1.4.3 France: Europe Human Microbiome Market Share – by Application
 - 10.1.1.4.4 France: Europe Human Microbiome Market Share – by Disease Type
- 10.1.1.5 Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.1.1.5.1 Italy: Europe Human Microbiome Market Share – by Type
 - 10.1.1.5.2 Italy: Europe Human Microbiome Market Share – by Product
 - 10.1.1.5.3 Italy: Europe Human Microbiome Market Share – by Application
 - 10.1.1.5.4 Italy: Europe Human Microbiome Market Share – by Disease Type
- 10.1.1.6 Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.1.1.6.1 Spain: Europe Human Microbiome Market Share – by Type
 - 10.1.1.6.2 Spain: Europe Human Microbiome Market Share – by Product
 - 10.1.1.6.3 Spain: Europe Human Microbiome Market Share – by Application
 - 10.1.1.6.4 Spain: Europe Human Microbiome Market Share – by Disease Type
- 10.1.1.7 Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 10.1.1.7.1 Rest of Europe: Europe Human Microbiome Market Share – by Type
 - 10.1.1.7.2 Rest of Europe: Europe Human Microbiome Market Share – by Product
 - 10.1.1.7.3 Rest of Europe: Europe Human Microbiome Market Share – by Application
 - 10.1.1.7.4 Rest of Europe: Europe Human Microbiome Market Share – by Disease Type

11. INDUSTRY LANDSCAPE

- 11.1 Overview
- 11.2 Growth Strategies in the Human Microbiome Market
- 11.3 Organic Growth Strategies
 - 11.3.1 Overview
- 11.4 Inorganic Growth Strategies
 - 11.4.1 Overview

12. COMPANY PROFILES

- 12.1 MaaT Pharma
 - 12.1.1 Key Facts
 - 12.1.2 Business Description
 - 12.1.3 Products and Services
 - 12.1.4 Financial Overview
 - 12.1.5 SWOT Analysis
 - 12.1.6 Key Developments
- 12.2 Ferring Holdings SA
 - 12.2.1 Key Facts
 - 12.2.2 Business Description
 - 12.2.3 Products and Services
 - 12.2.4 Financial Overview
 - 12.2.5 SWOT Analysis
 - 12.2.6 Key Developments
- 12.3 AOBiome Therapeutics Inc
 - 12.3.1 Key Facts
 - 12.3.2 Business Description
 - 12.3.3 Products and Services
 - 12.3.4 Financial Overview
 - 12.3.5 SWOT Analysis
 - 12.3.6 Key Developments
- 12.4 Finch Therapeutics Group Inc
 - 12.4.1 Key Facts
 - 12.4.2 Business Description
 - 12.4.3 Financial Overview
 - 12.4.4 SWOT Analysis
 - 12.4.5 Key Developments
- 12.5 Seres Therapeutics Inc
 - 12.5.1 Key Facts
 - 12.5.2 Business Description
 - 12.5.3 Products and Services
 - 12.5.4 Financial Overview
 - 12.5.5 SWOT Analysis
 - 12.5.6 Key Developments
- 12.6 Merck & Co Inc
 - 12.6.1 Key Facts
 - 12.6.2 Business Description
 - 12.6.3 Products and Services
 - 12.6.4 Financial Overview

- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Yakult Honsha Co., Ltd.
 - 12.7.1 Key Facts
 - 12.7.2 Business Description
 - 12.7.3 Products and Services
 - 12.7.4 Financial Overview
 - 12.7.5 SWOT Analysis
 - 12.7.6 Key Developments
- 12.8 Rebiotix, Inc.
 - 12.8.1 Key Facts
 - 12.8.2 Business Description
 - 12.8.3 Products and Services
 - 12.8.4 Financial Overview
 - 12.8.5 SWOT Analysis
 - 12.8.6 Key Developments
- 12.9 IFF Nutrition & Biosciences
 - 12.9.1 Key Facts
 - 12.9.2 Business Description
 - 12.9.3 Products and Services
 - 12.9.4 Financial Overview
 - 12.9.5 SWOT Analysis
 - 12.9.6 Key Developments
- 12.10 Synthetic Biologics, Inc.
 - 12.10.1 Key Facts
 - 12.10.2 Business Description
 - 12.10.3 Products and Services
 - 12.10.4 Financial Overview
 - 12.10.5 SWOT Analysis
 - 12.10.6 Key Developments

13. APPENDIX

- 13.1 About Us
- 13.2 List of Abbreviations

List Of Tables

LIST OF TABLES

Table 1. Europe Human Microbiome Market Segmentation

Table 2. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Table 3. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million) – by Type

Table 4. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million) – by Application

Table 5. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million) – by Disease Type

Table 6. Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million) – by Country

Table 7. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Type

Table 8. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Product

Table 9. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Application

Table 10. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Disease Type

Table 11. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Type

Table 12. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Product

Table 13. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Application

Table 14. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Disease Type

Table 15. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Type

Table 16. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Product

Table 17. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Application

Table 18. France: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Disease Type

Table 19. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 –

2031 (US\$ Million) – by Type

Table 20. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Product

Table 21. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Application

Table 22. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Disease Type

Table 23. ADULT OBESITY, 2030

Table 24. CHILD OBESITY, 2030

Table 25. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Type

Table 26. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Product

Table 27. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Application

Table 28. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Disease Type

Table 29. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Type

Table 30. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Product

Table 31. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Application

Table 32. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US\$ Million) – by Disease Type

Table 33. Recent Organic Growth Strategies in the Human Microbiome Market

Table 34. Recent Inorganic Growth Strategies in the Human Microbiome Market

Table 35. List of Abbreviations

List Of Figures

LIST OF FIGURES

Figure 1. Europe Human Microbiome Market Segmentation – Country

Figure 2. PEST Analysis

Figure 3. Europe Human Microbiome Market – Key Market Dynamics

Figure 4. Impact Analysis of Drivers and Restraints

Figure 5. Europe Human Microbiome Market Revenue (US\$ Million), 2021–2031

Figure 6. Europe Human Microbiome Market Share (%) – by Type (2023 and 2031)

Figure 7. Product: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 8. Software and Services: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 9. Europe Human Microbiome Market Share (%) – by Application (2023 and 2031)

Figure 10. Therapeutics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 11. Diagnostics: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 12. Research: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 13. Europe Human Microbiome Market Share (%) – by Disease Type (2023 and 2031)

Figure 14. Obesity: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 15. Diabetes: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 16. Autoimmune Disorder: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 17. Cancer: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 18. GIT: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 19. Others: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 20. Europe Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 21. United Kingdom: Europe Human Microbiome Market – Revenue and Forecast, 2021–2031 (US\$ Million)

Figure 22. Germany: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US\$ Million)

Figure 23. France: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US\$ Million)

Figure 24. Italy: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US\$ Million)

Figure 25. Spain: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US\$ Million)

Figure 26. Rest of Europe: Europe Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US\$ Million)

Figure 27. Growth Strategies in the Human Microbiome Market

I would like to order

Product name: Europe Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Product link: <https://marketpublishers.com/r/E415B96D3FCFEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E415B96D3FCFEN.html>